Ten‐year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double‐blind, placebo‐controlled trial on symptomatic patients
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Combined medical treatment may provide further benefit to primary biliary cirrhosis (PBC) patients administered ursodeoxycholic acid (UDCA). Aim: To evaluate the long‐term effects of colchicine and UDCA in symptomatic PBC patients. Patients/methods: We extended up to 10 years the double‐blind treatment of 44 symptomatic PBC patients originally included in a 3‐year multicentre study comparing UDCA and colchicine (U + C) versus UDCA and placebo (U + P). Outcome measures were death or liver transplantation; incidence of clinically relevant events; clinical and quantitative variables retaining prognostic information. Results: Mean follow‐up was 7 ± 3 years. One patient was lost, three withdrew because of jaundice (U + P); two patients stopped colchicine but remained on UDCA. Eleven patients (two for liver‐unrelated reasons, U + P) and six patients (U + C) died, three and two patients, respectively, were transplanted (incidence rate difference, five cases per 100 patient‐years; 95% CI, −1 to 11). Hepatocellular carcinoma developed in one (U + P) and four (U + C) patients (difference, −2; CI, −5 to 1), portal hypertension complications in nine patients from each group (difference, 1; CI, −5 to 6). Trends of serum bilirubin, Mayo score, antipyrine clearance were similar among treatment groups. Conclusions: In cirrhotic PBC patients, colchicine does not offer additional benefits to UDCA. In this population, UDCA does not obviate disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes
Jones, D. E., Metcalf, J. V., Collier, J. D., Bassendine, M. F., & James, O. F. (1997) · Hepatology · doi:10.1002/hep.510260508 · Cited by 161
Cited by
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.017 · Cited by 394
Tsukada, S., Parsons, C. J., & Rippe, R. A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.014 · Cited by 357
Ursodeoxycholic Acid for the Treatment of Primary Biliary Cirrhosis
Lindor, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmct074694 · Cited by 115
Lens, S., Leoz, M., Nazal, L., Bruguera, M., & Parés, A. (2014) · Liver International · doi:10.1111/liv.12290 · Cited by 107
“Because of this, further treatments have been assessed, including the combination with budesonide (6, 7), other drugs such as colchicine (8), methotrexate (9) or silymarin (10), or newer agents such as obeticholic acid (11).”
Background
Metadata
- Authors
- Battezzati, P. M., Zuin, M., Crosignani, A., Allocca, M., Invernizzi, P., Selmi, C., Villa, E., & Podda, M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2001-09-27
- Volume
- 15
- Issue
- 9
- Pages
- 1427-1434
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2143134288
- Cited by
- 38
- References
- 3
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ten‐year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double‐blind, placebo‐controlled trial on symptomatic patients. https://app.cochat.ai/papers/10.1046/j.1365-2036.2001.01018.x
- The paper
- Battezzati, P. M., Zuin, M., Crosignani, A., Allocca, M., Invernizzi, P., Selmi, C., Villa, E., & Podda, M. (2001). Ten‐year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double‐blind, placebo‐controlled trial on symptomatic patients. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2001.01018.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.